Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Various intranasal sedatives in canaries
Canaries are patients which are difficult to anesthesize - as well by injection as by inhalation. The intranasal application seems to be a fascinating alternative. Can it be recommended? It can, as this new prospective randomized study shows.

In this study the effects of intranasal benzodiazepines (midazolam and diazepam), á2-agonists (xylazine and detomidine) and their antagonists (flumazenil and yohimbine) in canaries were investigated. Twenty-six healthy adult domesticated canaries of both sexes, weighing 18.3 ± 1.0 g were included.

In Study 1 an attempt was made to determine the dose of each drug that allowed treated canaries to be laid in dorsal recumbency for at least 5 minutes, i.e. its effective dose.

This involved the evaluation of various doses, during which equal volumes of the tested drug were administered slowly into each nostril.

In study 2 the onset of action, duration and quality of sedation induced by each drug at its effective dose were evaluated. The efficacy of flumazenil and yohimbine in antagonizing the effects of the sedative drugs was also studied.

Results: In study 1 administration of 25 ìL per nostril diazepam (5 mg mL1 solution) or midazolam (5 mg mL1 solution) to each bird caused adequate sedation within 1–2 minutes; birds did not move when placed in dorsal recumbency.

After administration of 12 ìL per nostril of either xylazine (20 mg mL1) or detomidine (10 mg mL1), birds seemed heavily sedated and assumed sternal recumbency but could not be placed in dorsal recumbency.

Higher doses of xylazine (0.5 mg per nostril) or detomidine (0.25 mg per nostril) prolonged sedation but did not produce dorsal recumbency.

In study 2 in all treatment groups, onset of action was rapid. Duration of dorsal recumbency was significantly longer (p < 0.05) with diazepam (38.4 ± 10.5 minutes) than midazolam (17.1 ± 2.2 minutes).

Intranasal flumazenil (2.5 ìg per nostril) significantly reduced recumbency time. Duration of sedation was longer with á2-agonists compared with benzodiazepines. Detomidine had the longest duration of effect (257.5 ± 1.5 minutes) and midazolam the shortest (36.9 ± 2.4 minutes).

Nasally administered flumazenil significantly reduced the duration of sedation with diazepam and midazolam while yohimbine (120 ìg per nostril) effectively antagonized the effects of xylazine and detomidine.

Conclusion: Intranasal benzodiazepines produce rapid and effective sedation in canaries. Intranasal á2 agonists produce sedation but not sustained recumbency. Specific antagonists are also effective when used by this route.

Thus, intranasal sedative drug administration is an acceptable alternative method of drug delivery in canaries.


Source: Vesal, Nasser & Zare, Payman (2006): Clinical evaluation of intranasal benzodiazepines, á2-agonists and their antagonists in canaries. In: Veterinary Anaesthesia and Analgesia 33 (3), 143-148.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Variability of SDMA in apparently healthy dogsmembers
Symmetric dimethylarginine (SDMA) is a screening tool for early kidney dysfunction and monitoring treatment in cases of chronic kidney disease (CKD). There are no current studies describing the suitability of this test for use with published population‐based reference intervals. The objectives of this study were to determine the components of biological variability, the index of individuality (IOI), the critical difference between sequential measurements (CD) and the number of measurements required to assess the homeostatic set point (HSP), for both SDMA and serum creatinine (sCr), in apparently healthy dogs.

  • Bioavailability of suppository acetaminophen in dogsmembers
  • Computed tomographic lymphography for lymph node staging in dogs with malignant tumors members
  • Characterization of ocular melanosis-affected canine melanocytesmembers
  • Nasopharyngeal sialoceles in brachycephalic dogsmembers
  • Enterococcus faecium SF68 on serum cobalamin and folate concentrationsmembers
  • Gastrointestinal eosinophilic sclerosing fibroplasia limited to the mesentery in a catmembers
  • Ion acid-base disturbances and associated mortality in dogsmembers
  • First description of ultrasonic bone curette in canine otic surgerymembers
  • Staining hair samples with a modified Wright-Giemsa stain to diagnose feline dermatophytosismembers
  • Oral extended release hydrocodone as analgesia after TPLOmembers
  • 25OH vitamin D3 serum concentration in dogs with acute polyradiculoneuritismembers
  • Type 1 immune mediated polyarthritis in dogs and temporal relationship to vaccination members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved